[DOI] [PMC free article] [PubMed] [Google Scholar] 61.Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrm SZ, Davies MJ, Hovingh GK, Kitzman DW, Mller DV, Verma S, Einfeldt MN, Lindegaard ML, Rasmussen S, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovsk V, Merkely B, Nez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Kosiborod MN STEP-HFpEF Trial Committees and Investigators
The SURPASS clinical trial program did not identify increased cardiovascular events with tirzepatide compared to placebo or active comparators, though dedicated cardiovascular outcome trials are still ongoing
Prefer to use insurance
And whether you have insurance or not, QuickMD is here to help make getting your medications as convenient and as affordable as possible
For now, however, the vision loss lawsuits remain outside the existing MDL framework